ReviewInternational immunopharmacology2021
COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology.
Review in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Role of nanoclusters in the design and development of novel strategies for diagnosis and treatment of infectious diseases.Nanoscale advances · 2026Review
- RepurNet: A network medicine framework for systematic drug repurposing and disease vulnerability discovery.iScience · 2026Article
- Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS-CoV-2 (COVID-19).Prostate cancer · 2026Article
- Cancer burden and the contributions of risk factors in China: A systematic analysis for the Global Burden of Disease Study 2021.Chinese medical journal · 2025Article
- Changes in cancer-related mortality during the COVID-19 pandemic (2020-2021) in Nevada.Discover oncology · 2025Article
- Carbon dot-lipidoid nanocarriers for superiorly biocompatible nasal mRNA cancer vaccination.Journal of nanobiotechnology · 2025Article
- The Role of Dendritic Cells in Adaptive Immune Response Induced by OVA/PDDA Nanoparticles.Vaccines · 2025Article
- Comprehensive Analysis of Potential Common Pathogenic Mechanisms for COVID-19 Infection and Gastric Cancer.Analytical cellular pathology (Amsterdam) · 2025Article
- Revolutionizing oncology care: pioneering AI models to foresee pneumonia-related mortality.Frontiers in oncology · 2025Article
- Knowledge about, attitudes toward and acceptance and predictors of intention to receive the mpox vaccine among cancer patients in China: A cross-sectional survey.Human vaccines & immunotherapeutics · 2024Article
- Completion rates and myelosuppression degrees of cancer patients receiving radiotherapy or chemoradiotherapy unchanged regardless of delay duration after Omicron infection.Scientific reports · 2024Article
- The Effect of Coronavirus Disease 2019 on the Quality of Associated Care in Patients with Gastric Cancer.Middle East journal of digestive diseases · 2024Review
- Investigating the potential mechanism of quercetin against cervical cancer.Discover oncology · 2023Article
- BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours.Molecular cancer · 2023Article
- Metal-Organic Framework/Polyvinyl Alcohol Composite Films for Multiple Applications Prepared by Different Methods.Membranes · 2023Review
- Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.Functional & integrative genomics · 2023Article
- An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics.Pharmaceutics · 2023Review
- Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model.Molecular therapy. Methods & clinical development · 2023Article
- Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers.International journal of molecular sciences · 2023Review
- Non-Dexamethasone Corticosteroid Therapy's Effect on COVID-19 Prognosis in Cancer Patients: A Retrospective Study.Vaccines · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic which has induced unprecedented ramifications, severely affecting our society due to the long incubation time, unpredictably high prevalence and lack of effective vaccines. One of the interesting notions is that there is an association between COVID-19 and cancer. Cancer patients seem to exhibit exacerbated conditions and a higher mortality rate when exposed to the virus. Therefore, vaccines are the promising solution to minimise the problem amongst cancer patients threatened by the new viral strains. However, there are still limitations to be considered, including the efficacy of COVID vaccines for immunocompromised individuals, possible interactions between the vaccine and cancer, and personalised medicine. Not only to eradicate the pandemic, but also to make it more effective for immunocompromised patients who are suffering from cancer, a successful vaccine platform is required through the implementation of nanotechnology which can also enable scalable manufacturing and worldwide distribution along with its faster and precise delivery. In this review, we summarise the current understanding of COVID-19 with clinical perspectives, highlighting the association between COVID-19 and cancer, followed by a vaccine development for this association using nanotechnology. We suggest different administration methods for the COVID-19 vaccine formulation options. This study will contribute to paving the way towards the prevention and treatment of COVID-19, especially for the immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.